San Diego, California –- Dr. Abdulkader Rahmo, President and Chief Scientific Officer at SMSbiotech, presented at the Drug Discovery Innovation Programme 2025 on March 3-4, 2025, at the Hilton San Diego Bayfront, California.
Dr. Rahmo’s presentation, “Using SMS Cells to Overcome the Many Bottlenecks of Regenerative Cell Therapy,” will explore the groundbreaking potential of Small Mobile Stem (SMS) Cells in overcoming critical challenges in regenerative medicine. By addressing key limitations in current cell therapies, Small Mobile Stem cells (SMS) introduce a novel approach to solve the persistent unmet need presented by chronic diseases such as Chronic Obstructive Pulmonary Disease (COPD) and others.
About the Drug Discovery Innovation Programme 2025:
The Drug Discovery Innovation Programme is a premier invitation-only event that brings together global leaders in drug development, biotechnology, and medical research. This exclusive conference fosters collaboration among the brightest minds in drug discovery, providing a platform to exchange insights, share experiences, and establish strategic partnerships with key industry leaders and solution providers.
Dr. Rahmo looks forward to sharing insights, engaging with fellow experts, and advancing the conversation on next-generation regenerative therapies.
Contact:
For more information about the Drug Discovery Innovation Programme 2025 or to arrange a meeting with Dr. Rahmo, please contact a.rahmo@smsbiotech.com
